Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Rhea-AI Summary
Roivant (Nasdaq: ROIV) will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026 to report financial results for the third quarter ended December 31, 2025 and provide a business update.
Investors can register for phone access online and view the presentation and live webcast under Events & Presentations in the Investors section at https://investor.roivant.com/news-events/events. An archived webcast will be available on Roivant’s website after the call.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ROIV was roughly flat (-0.04%) while key biotech peers were mixed: MRNA +3.24%, MDGL +0.22%, VRNA +0.06%, BPMC +0.09%, HALO -0.90%. No clear sector‑wide move tied to this scheduling news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Investor Day update | Positive | +5.4% | Outlined accelerated late‑stage timelines and multiple planned launches and filings. |
| Nov 10 | Earnings and pipeline | Positive | +2.7% | Reported Q2 results with positive Phase 3 data and strong cash position. |
| Oct 27 | Earnings date notice | Neutral | -2.1% | Announced date and logistics for Q2 2025 earnings call and webcast. |
| Sep 17 | Phase 3 trial win | Positive | +7.8% | Reported brepocitinib superiority in 52‑week placebo‑controlled VALOR dermatomyositis study. |
| Sep 11 | Workplace recognition | Positive | -2.3% | Named to Fortune and Great Place To Work 2025 Best Workplaces in BioPharma list. |
Recent news with substantive clinical or strategic content (Investor Day, Phase 3 data, earnings with strong updates) corresponded to positive moves, while softer or reputational news and prior scheduling announcements saw modest declines. The stock has generally reacted more strongly to clinical and pipeline milestones than to event‑date notices.
Over the past several months, Roivant has highlighted significant clinical and strategic progress. A positive Phase 3 VALOR dermatomyositis readout on Sep 17, 2025 and the 2025 Investor Day on Dec 11, 2025 both coincided with notable gains. The Q2 2025 earnings release on Nov 10, 2025 also saw a positive reaction. By contrast, a prior earnings‑date announcement on Oct 27, 2025 and a workplace recognition news item on Sep 11, 2025 corresponded with modest declines, underscoring that investors focus more on data‑rich updates than on procedural or reputational news.
Regulatory & Risk Context
An effective Form S-3ASR dated October 3, 2025 permits Roivant to offer common shares and other securities, including up to $400.0 million of common shares via a Sales Agreement, with $0 sold as of filing. The company also maintains an active share repurchase program and indicates it may or may not use this registration statement.
Market Pulse Summary
This announcement sets the date and time of Roivant’s next earnings call on Feb 6, 2026, without disclosing financial figures or new clinical data. Historically, the stock has reacted more strongly to substantive updates, such as the Phase 3 VALOR results and Investor Day disclosures, than to scheduling notices. Investors may focus on how upcoming results compare with prior clinical milestones and strategic objectives discussed in recent quarters.
AI-generated analysis. Not financial advice.
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update.
To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
When will Roivant (ROIV) report third quarter results and hold the webcast?
What period will Roivant (ROIV) report on during the February 6, 2026 call?
How can investors access the Roivant (ROIV) conference call by phone?
Where will Roivant (ROIV) post the webcast and presentation for the February 6, 2026 call?
Will the Roivant (ROIV) webcast be available after the live event?
Is registration required to attend Roivant's (ROIV) February 6, 2026 conference call?
